Lake Street Advisors Group LLC Reduces Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Lake Street Advisors Group LLC decreased its position in AstraZeneca PLC (NASDAQ:AZN) by 2.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,675 shares of the company’s stock after selling 314 shares during the period. Lake Street Advisors Group LLC’s holdings in AstraZeneca were worth $832,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its holdings in shares of AstraZeneca by 17.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after purchasing an additional 9,002,450 shares during the period. Swedbank AB bought a new position in shares of AstraZeneca during the first quarter valued at about $186,127,000. Manning & Napier Advisors LLC bought a new position in shares of AstraZeneca during the second quarter valued at about $188,476,000. Hsbc Holdings PLC grew its stake in shares of AstraZeneca by 750.3% during the second quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock valued at $100,523,000 after buying an additional 1,132,362 shares during the last quarter. Finally, Farallon Capital Management LLC boosted its holdings in shares of AstraZeneca by 65.1% during the second quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock worth $187,934,000 after purchasing an additional 950,000 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. TD Cowen upped their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Price Performance

NASDAQ AZN opened at $75.05 on Friday. The business’s fifty day moving average price is $80.40 and its 200-day moving average price is $78.44. The stock has a market capitalization of $232.69 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 1.43 and a beta of 0.46. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The firm had revenue of $12.45 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the prior year, the firm earned $1.08 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. On average, equities analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.